Biogen Idec will take over full ownership of the multiple sclerosis treatment Tysabri from its partner Irish drugmaker Elan Corp. PLC in exchange for a $3.25 billion cash payment and royalties…
Search Results - stltoday.com, St. Louis Post-Dispatch: Business
Wed, 02/06/2013 - 5:27am